Acute Retinal Pigment Epithelium Tear Four Days Post Intravitreal Aflibercept Injection: A Case Report |Biomedgrid

Retinal Pigment Epithelium (RPE) tear is an uncommon but recognized complication of anti-Vascular Endothelial Growth Factor (anti-VEGF) treatment for neovascular age-related macular degeneration. This has predominantly been reported in association with bevacizumab (Avastin), ranibizumab (Lucentis), and pegaptanib (Macugen). Herein, we report a unique case of early RPE tear four days following an intravitreal aflibercept (Eylea) injection. To the best of our knowledge, this describes the earliest RPE tear following intravitreal aflibercept injection.